CL2016000362A1 - Bispecific monovalent diabodies that are capable of joining cd 123 and cd3, and uses thereof - Google Patents
Bispecific monovalent diabodies that are capable of joining cd 123 and cd3, and uses thereofInfo
- Publication number
- CL2016000362A1 CL2016000362A1 CL2016000362A CL2016000362A CL2016000362A1 CL 2016000362 A1 CL2016000362 A1 CL 2016000362A1 CL 2016000362 A CL2016000362 A CL 2016000362A CL 2016000362 A CL2016000362 A CL 2016000362A CL 2016000362 A1 CL2016000362 A1 CL 2016000362A1
- Authority
- CL
- Chile
- Prior art keywords
- joining
- bispecific monovalent
- diabodies
- monovalent diabodies
- bispecific
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se dirige a los diacuerpos biespecificos monovalentes de secuencia optimizada CD123 x CD3 que son capaces de unión simultánea a CD123 y CD3, y a los usos de tales diacuerpos en el tratamiento de malignidades hematológicas. La invención también se refiere a composiciones farmacéuticas y usosThe present invention is directed to monovalent bispecific diabodies of optimized sequence CD123 x CD3 that are capable of simultaneous binding to CD123 and CD3, and to the uses of such diabodies in the treatment of hematological malignancies. The invention also relates to pharmaceutical compositions and uses.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869510P | 2013-08-23 | 2013-08-23 | |
| US201361907749P | 2013-11-22 | 2013-11-22 | |
| EP13198784.4A EP2839842A1 (en) | 2013-08-23 | 2013-12-20 | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| US201461990475P | 2014-05-08 | 2014-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000362A1 true CL2016000362A1 (en) | 2016-10-28 |
Family
ID=65632998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000362A CL2016000362A1 (en) | 2013-08-23 | 2016-02-17 | Bispecific monovalent diabodies that are capable of joining cd 123 and cd3, and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| CL (1) | CL2016000362A1 (en) |
| DK (1) | DK3035965T3 (en) |
| ES (1) | ES2860973T3 (en) |
| GE (1) | GEP20197053B (en) |
| HR (1) | HRP20210215T1 (en) |
| HU (1) | HUE054315T2 (en) |
| LT (1) | LT3035965T (en) |
| UA (1) | UA119539C2 (en) |
-
2014
- 2014-08-20 UA UAA201602538A patent/UA119539C2/en unknown
- 2014-08-20 DK DK14837858.1T patent/DK3035965T3/en active
- 2014-08-20 LT LTEP14837858.1T patent/LT3035965T/en unknown
- 2014-08-20 GE GEAP201414100A patent/GEP20197053B/en unknown
- 2014-08-20 ES ES14837858T patent/ES2860973T3/en active Active
- 2014-08-20 HR HRP20210215TT patent/HRP20210215T1/en unknown
- 2014-08-20 HU HUE14837858A patent/HUE054315T2/en unknown
-
2016
- 2016-02-17 CL CL2016000362A patent/CL2016000362A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1225999A1 (en) | 2017-09-22 |
| HUE054315T2 (en) | 2021-08-30 |
| UA119539C2 (en) | 2019-07-10 |
| DK3035965T3 (en) | 2021-02-15 |
| LT3035965T (en) | 2021-04-12 |
| ES2860973T3 (en) | 2021-10-05 |
| NZ716914A (en) | 2021-09-24 |
| HRP20210215T1 (en) | 2021-04-16 |
| GEP20197053B (en) | 2019-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160509A1 (en) | BISPECIFIC MONOVALENT DIACBODIES THAT ARE CAPABLE OF JOINING CD123 AND CD3 AND USING THE SAME | |
| CL2018000422A1 (en) | Bispecific monovalent diabodies that are capable of binding to b7-h3 and cd3, and uses thereof | |
| MX375669B (en) | Bispecific monovalent diabodies that are capable of binding CD19 and CD3, and their uses. | |
| CY1123236T1 (en) | BISPECIFIC ANTIBODIES THAT BIND TO CD38 AND CD3 | |
| CL2017002752A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antibodies | |
| ECSP17040521A (en) | Heterodimeric antibodies that bind to CD3 and tumor antigens | |
| IL256871B (en) | Constructs for bispecific antibodies binding to dll3 and cd3 and uses thereof | |
| MX373245B (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES. | |
| AR088171A1 (en) | ANTI-ERBB3 ANTIBODIES AND USES OF THE SAME | |
| MX2016001236A (en) | Afucosylated anti-fgfr2iiib antibodies. | |
| CL2017001361A1 (en) | Heterodimeric antibodies that bind to cd3 and cd38 | |
| CR20150502A (en) | SPECIFIC BIESPECTIFIC ANTIBODIES FOR FAP AND DR5, SPECIFIC ANTIBODIES FOR DR5 AND METHODS OF USE | |
| UY35483A (en) | PAC1 HUMAN ANTIBODIES | |
| CL2014002616A1 (en) | Bispecific anti-baff-anti-il-17 antibodies; compositions that contain it and its uses. | |
| MX2018003183A (en) | Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof. | |
| MX373308B (en) | COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB. | |
| CL2016000362A1 (en) | Bispecific monovalent diabodies that are capable of joining cd 123 and cd3, and uses thereof | |
| AR105714A1 (en) | MONOVALENT BIESPECFIC DIACUMS THAT ARE ABLE TO JOIN B7-H3 AND CD3, AND USES OF THE SAME | |
| CR20170222A (en) | HETERODIMERIC ANTIBODIES THAT JOIN CD3 AND TUMOR ANTIGENS |